| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
6.11(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,241,765 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
91,318 |
224,559 |
397,579 |
888,401 |
| Total Sell Value |
$6,319,460 |
$16,400,468 |
$22,217,779 |
$44,103,545 |
| Total People Sold |
2 |
4 |
5 |
11 |
| Total Sell Transactions |
4 |
15 |
35 |
82 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Henderson John T |
Director |
– • – |
2021-10-01 |
4 |
A |
$36.74 |
$11,242 |
D/D |
306 |
13,255 |
|
- |
|
| Cragg David |
Chief HR & Admin Officer |
• – – |
2021-10-01 |
4 |
AS |
$35.14 |
$265,990 |
D/D |
(7,569) |
137,123 |
|
10% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-09-30 |
4 |
AS |
$34.01 |
$170,064 |
D/D |
(5,000) |
357,563 |
|
10% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-09-30 |
4 |
OE |
$6.00 |
$30,000 |
D/D |
5,000 |
362,563 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2021-09-15 |
4 |
AS |
$32.66 |
$163,317 |
D/D |
(5,000) |
357,563 |
|
-10% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-09-15 |
4 |
OE |
$6.00 |
$31,220 |
D/D |
5,000 |
361,628 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2021-09-09 |
4 |
AS |
$31.43 |
$62,860 |
D/D |
(2,000) |
152,878 |
|
3% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-09-02 |
4 |
AS |
$33.12 |
$165,577 |
D/D |
(5,000) |
357,563 |
|
-2% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-09-02 |
4 |
OE |
$6.30 |
$31,500 |
D/D |
5,000 |
362,563 |
|
- |
|
| Cragg David |
Chief HR & Admin Officer |
• – – |
2021-09-01 |
4 |
AS |
$32.78 |
$257,311 |
D/D |
(7,850) |
144,692 |
|
3% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-08-18 |
4 |
AS |
$31.14 |
$155,712 |
D/D |
(5,000) |
357,563 |
|
53% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-08-18 |
4 |
OE |
$6.30 |
$31,500 |
D/D |
5,000 |
362,563 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2021-08-12 |
4 |
AS |
$32.60 |
$65,200 |
D/D |
(2,000) |
154,878 |
|
36% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-08-05 |
4 |
AS |
$29.12 |
$145,604 |
D/D |
(5,000) |
357,563 |
|
23% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-08-05 |
4 |
OE |
$6.30 |
$31,500 |
D/D |
5,000 |
362,563 |
|
- |
|
| Cragg David |
Chief HR & Admin Officer |
• – – |
2021-08-02 |
4 |
AS |
$29.67 |
$77,617 |
D/D |
(2,616) |
152,542 |
|
22% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-07-22 |
4 |
AS |
$29.82 |
$149,121 |
D/D |
(5,000) |
357,563 |
|
29% |
|
| Blum Robert I |
President & CEO |
• • – |
2021-07-22 |
4 |
OE |
$6.30 |
$31,500 |
D/D |
5,000 |
362,563 |
|
- |
|
| Smith Sandford D |
Director |
– • – |
2021-07-19 |
4 |
AS |
$28.50 |
$345,468 |
D/D |
(11,965) |
6,459 |
|
49% |
|
| Smith Sandford D |
Director |
– • – |
2021-07-19 |
4 |
OE |
$10.68 |
$127,786 |
D/D |
11,965 |
11,459 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2021-07-08 |
4 |
AS |
$19.48 |
$38,952 |
D/D |
(2,000) |
156,878 |
|
99% |
|
| Henderson John T |
Director |
– • – |
2021-07-07 |
4 |
A |
$19.77 |
$1,246 |
D/D |
63 |
12,949 |
|
- |
|
| Wierenga Wendall D |
Director |
– • – |
2021-07-07 |
4 |
A |
$19.77 |
$1,246 |
D/D |
63 |
6,459 |
|
- |
|
| Wysenski Nancy |
Director |
– • – |
2021-07-07 |
4 |
A |
$19.77 |
$613 |
D/D |
31 |
5,728 |
|
- |
|
| Smith Sandford D |
Director |
– • – |
2021-07-07 |
4 |
A |
$19.77 |
$1,246 |
D/D |
63 |
6,459 |
|
- |
|
710 Records found
|
|
Page 15 of 29 |
|
|
1.36 (2.8%) 
